|
| Press Releases |
|
 |
|
| Tuesday, October 28, 2025 |
|
|
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma |
| more info >> |
|
| Monday, October 27, 2025 |
|
|
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease |
| more info >> |
|
| Tuesday, October 14, 2025 |
|
|
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that LEQEMBI(R) IQLIK(TM), a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease (AD) has been selected by TIME as one of the "Best Inventions of 2025" in the Medical and Healthcare category. more info >> |
|
| Wednesday, October 8, 2025 |
|
|
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIK(TM) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Friday, October 3, 2025 |
|
|
Eisai Highlights Breadth of Oncology Research at ESMO 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2025, which is taking place in Berlin, Germany from October 17 to 21. more info >> |
|
| Monday, September 29, 2025 |
|
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI(R)" (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the National Medical Products Administration (NMPA) in China. more info >> |
|
| Wednesday, September 24, 2025 |
|
|
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD) (collectively referred to as early AD) in adults who are either ApoEε4* non-carriers or heterozygous carriers. more info >> |
|
| Wednesday, September 17, 2025 |
|
|
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). more info >> |
|
| Friday, September 12, 2025 |
|
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the release of a concept movie and new content on the dedicated website for its "New Answers to Dementia" campaign, designed to increase corporate awareness. more info >> |
|
| Monday, September 8, 2025 |
|
|
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
PropertyGuru Asia Real Estate Summit spotlights PropertyGuru Week 2025 with conversations on 'Trusted Marketplaces and Thriving Communities'
Dec 18, 2025 09:00 HKT/SGT
|
|
|
TruMerit 與 NAPNAP 攜手開發全球性小微認證，專注於兒科護理照護領域
Dec 18, 2025 07:00 HKT/SGT
|
|
|
TruMerit与NAPNAP携手开发全球儿科护理微认证
Dec 18, 2025 07:00 HKT/SGT
|
|
|
TruMerit and NAPNAP Team Up to Develop a Global Micro-credential for Pediatric Nursing Care
Dec 18, 2025 07:00 HKT/SGT
|
|
|
1World Online and Culinary Heritage Announce Strategic Partnership and Joint Launches in Europe
Dec 17, 2025 23:29 HKT/SGT
|
|
|
キリンと富士通、創薬DX技術を活用し、AIと実試験でシチコリンの腸脳作用メカニズムを解明
Dec 17, 2025 15:30: JST
|
|
|
マツダ、「D&I AWARD」において最上位「ベストワークプレイス」に2年連続認定
Dec 17, 2025 12:00: JST
|
|
|
Anson Resources: Update on Cooperation between Anson and POSCO Holdings for DLE Green River Demonstration Plant
Dec 17, 2025 07:00 HKT/SGT
|
|
|
AWM 以多座衝浪場館盛大開幕，為 2025 年劃下完美句點
Dec 16, 2025 23:05 HKT/SGT
|
|
|
AWM Wraps Up 2025 with Multiple Surf Venue Grand Openings
Dec 16, 2025 23:05 HKT/SGT
|
|
|
伊士曼、阿斯特捷利康、卡夫亨氏與寶潔榮獲OMP供應鏈大獎
Dec 16, 2025 22:00 HKT/SGT
|
|
|
伊士曼、阿斯利康、卡夫亨氏和宝洁荣获OMP供应链大奖
Dec 16, 2025 22:00 HKT/SGT
|
|
|
Eastman, AstraZeneca, Kraft Heinz, and P&G Recognized with OMP Supply Chain Awards
Dec 16, 2025 22:00 HKT/SGT
|
|
|
Doubleview Gold Corp Extends Mineralization East of 2024 Conceptual Pit and Identifies Deeper Porphyry Indicators at Hat Project by Drilling 992m of 0.29% CuEq in Hole H101
Dec 16, 2025 20:29 HKT/SGT
|
|
|
美國馬球協會棕櫚灘馬拉松於佛羅里達州西棕櫚灘創下破紀錄的週末盛事
Dec 16, 2025 20:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
